Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

346.95 +3.42 (+1.00%)
Streaming Delayed Price Updated: 11:03 AM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Senator Mullin Discloses Stock Trades 2.5 Years After They Were Made, Including One Up 134.5%
 
Via Benzinga
Looking Into Insulet's Recent Short Interest
 
Via Benzinga
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Healthcare Stock on Our Buy List and 2 to Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
An update on Sana Biotechnology. 
Via Benzinga
2 High-Flying Stocks to Target This Week and 1 to Avoid
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
From Insulet Corporation
Via Business Wire
2 Mid-Cap Stocks Worth Your Attention and 1 to Brush Off
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Supply Chain
3 Growth Stocks to Stash
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
Topics Artificial Intelligence
Stay informed with the top movers within the S&P500 index on Tuesday.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process. 
Via Investor's Business Daily
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Via The Motley Fool
Topics Artificial Intelligence
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential
INSULET CORP (NASDAQ:PODD) shows strong revenue growth, high profitability, and a bullish technical setup, making it a noteworthy candidate for growth investors. 
Via Chartmill
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
From Insulet Corporation
Via Business Wire
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers. 
Via StockStory
Topics Artificial Intelligence
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
1 Cash-Producing Stock with Exciting Potential and 2 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Tuesday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Tuesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
From Insulet Corporation
Via Business Wire
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue... 
Via StockStory
Topics Economy World Trade
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
3 Medical Technology Stocks Outperforming in 2025
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns. 
Via MarketBeat
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
3 Reasons Investors Love Insulet (PODD)
While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to... 
Via StockStory
Topics Stocks
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.